跳至主要内容
临床试验/ACTRN12620000812998
ACTRN12620000812998已完成1 期

A multiple dose, randomized, open-label, pharmacokinetic study of a generic formulation of 5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone tablet in a 2 way crossover comparison against the innovator 5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone tablet administered 12 hours apart conducted under fasting conditions and at steady state in healthy volunteers.

Zenith Technology Corporation Limited0 个研究点目标入组 33 人开始时间: 2020年8月13日最近更新:

试验速览

阶段
1 期
状态
已完成
入组人数
33

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 55 Years(—)
性别
All

入选标准

  • Healthy males and non-pregnant females
  • Aged between 18 and 55 years
  • Non-smoker
  • BMI greater than or equal to 18.5 and less than 32 inclusive
  • Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
  • Drug free as determined by urine drug testing
  • Able to comply with the study restrictions
  • Able to provide written informed consent

排除标准

  • Clinically significant medical conditions
  • History of conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
  • History of alcohol or drug abuse or dependency
  • Participation in a drug study within 30 days of the start of the study
  • Sensitivitie to the study drug or excipients
  • Individuals for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk

研究者

相似试验